center experience, which included 1000 liver transplants, major adverse events potentially related to FK506 included neurotoxicity in 7%, insulin-dependent hyperglycemia in To determine how well tacrolimus (FK506) and cyclosporin A (CsA) are tolerated after HLA-identical blood 13-16%, hypertension in 29-39%, hyperkalemia in 42-47%, and significant infections in 10-36%. 7 Nephrotoxicstem cell transplantation, we performed a retrospective review of 87 adults transplanted consecutively who ity, manifested by magnesium wasting and a reduction in creatinine clearance, is the most serious side-effect of received FK506 (n = 40) or CsA (n = 47) in a nonrandomized fashion in combination with methylpredniso-FK506. Some degree of renal impairment has been reported in up to 48% of solid organ transplant recipients.
icity and to maintain whole-blood steady-state or trough Results levels of 5-15 ng/ml for FK506 by IMx assay and 250-350 ng/ml for CsA by RIA for parent drug to day 180 postCompliance transplant. The target range of FK506 levels was chosen on Actual drug dosing relative to the scheduled dose was simithe basis of an analysis demonstrating a correlation between lar in the two groups (Table 1) . Prior to the first conversion toxicity and FK506 levels for unrelated donor marrow and to oral administration, the median i.v. dose was 77% of the HLA-identical marrow transplant recipients, and doses initial dose for both FK506 and CsA. For the patients on were modified to maintain levels in the target range even oral drug at day 100, the median oral dose was 140% of in the absence of GVHD or toxicity.
11,12 Methylprednisothe initial FK506 dose vs 120% of the initial CsA dose (P lone was administered to all patients at 0.5 mg/kg i.v. twice = NS) for the respective groups of patients. This is less daily days 5-28 and tapered off over the subsequent month.
than the prescribed oral dosage (400% of the initial dose if the 1:4 conversion were used), suggesting that the 1:4 Statistical considerations conversion is too high. Overall, 27 patients discontinued use of FK506 or CsA prior to day 100, and the most comCharts were reviewed for renal insufficiency, dialysis, mon reasons were relapse or death unrelated to the drug. hyperkalemia, hypomagnesemia, neurologic complications, Four patients discontinued FK506 due to toxicity, six hyperbilirubinemia, veno-occlusive disease, hemolyticpatients discontinued CsA due to toxicity, and three patients uremic syndrome, fungal infections, and cytomegalovirus were converted from CsA to FK506 for treatment of infections within the first 100 days post-transplant. The out-GVHD. patient records for 77 patients discharged from the hospital were also reviewed for use of antihypertensive medication and use of insulin. One patient receiving cyclosporin A was Nephrotoxicity an outpatient only briefly and was not included in the outpatient review. Between group comparisons of demoMore than half the patients in each group had at least a doubling of the baseline serum creatinine, but there was no graphic data and toxicity were performed as indicated in the Tables using the Fisher exact test for nonparametric significant difference between the groups in the peak serum creatinine or in the proportion of patients with a creatinine data and the Mann-Whitney U test or paired t-test for measures on a continuous scale. Actuarial estimates of time-tothat exceeded 2 mg/dl (Table 2) . A similar number of patients in both treatment groups required dialysis, and in event were calculated by the method of Kaplan and Meier and compared by the Gehan-Wilcoxon test.
all cases, dialysis was part of preterminal care for patients with multiorgan failure. Four patients on FK506 disconproportion of patients receiving busulfan-based chemotherapy. While this may confound the analysis of VOD, tinued drug prematurely for renal insufficiency including three during the preterminal phase and one for hemolyticthere are no data to suggest that the different preparative regimens used had different risks of inducing VOD in uremic syndrome. Six patients on CsA discontinued drug prematurely for renal insufficiency, including four during our patients. the preterminal phase and two who survived thereafter.
Infections

Metabolic complications
The most common fungal infection in both groups was invasive aspergillosis, but the rates of culture-documented Hyperkalemia (serum potassium Ͼ5.5 mEq/l) was more prevalent in the FK506 group, but not significantly so. For fungemia and tissue infections were not significantly different between groups (Table 2) . Culture-documented cytopatients who were discharged to the outpatient clinic, however, a significantly greater proportion in the CsA group megaloviral (CMV) infections (usually viremia) occurred in 18% of patients at risk despite the use of prophylactic was treated for hypertension, and a significantly greater proportion in the FK506 group required insulin for hyperganciclovir, and the incidence of CMV infection was similar in both groups. glycemia (Table 2) .
Neurologic complications
Discussion Seizures occurred in two patients on FK506 and in three patients on CsA. Altered mental status manifested by conIn randomized studies or comparative analyses of liver transplant recipients, the toxicity profile of FK506 has been fusion or lethargy with or without seizures was seen in few patients in both groups. This occurred frequently in the setlargely similar to that of CsA. 8,13-17 In our series of patients treated in a nonrandomized fashion, FK506 was also tolerting of complex metabolic abnormalities, sepsis and/or infectious encephalitis.
ated as well as CsA by the allogeneic blood stem cell transplant recipients. The only disadvantage found for use of FK506 was the higher proportion of patients who required Hepatic complications insulin. FK506 is known to inhibit insulin secretion more than does CsA, and this difference in activity is thought to Median peak serum total bilirubin was significantly higher in the CsA group during the first 2 months post-transplant result from the high levels of FKBP-12, the FK506-binding protein, in pancreatic beta cells. 18, 19 In concert with this (Table 2 ). However, it should be noted that the CsA group also had a higher incidence of acute GVHD and a higher effect, the insulin requirement for the FK506 group could or in combination with methotrexate or methylprednisolone then be amplified by the diabetogenic effects of methylfor the prevention of acute graft-versus-host disease after marprednisolone used as part of the GVHD prophylaxis regi- 
